Welcome to Zomedica's Fourth Friday at Four webinar series. Today, we'll examine the Five Pillars framework, the operational foundation that guides every product, partnership, and investment decision at Zomedica. We'll walk through each pillar, the products behind them, and what the framework means for veterinary practice performance and long-term recurring growth.
Before we begin, I want to remind current and potential investors that we will be making various remarks about future expectations, plans, and prospects that are considered forward-looking statements.
There are risks that actual results may differ from these statements. We refer you to the safe harbor statement on screen or to the risk factors sections of our public filings, which can be found on our website under Investor Filings, EDGAR, and SEDAR+. The statements are made as of today, June 26th, 2026, and reflect our expectations as of today.
Thank you for joining us for Zomedica's Investor webinar series. We're excited to have you with us as we take a closer look at our company, our innovative product platforms, and the passionate people driving our success. This series is designed to give you a deeper understanding of how we're delivering value to veterinarians and to our shareholders.
At Zomedica, our mission is to deliver innovative diagnostic and therapeutic technologies that empower veterinarians to focus on what they love most, enhancing pet care and improving pet parent satisfaction. Equally important, we help vets with what they need most, streamlining workflow, increasing cash flow, and boosting practice profitability. Let's hear from Larry Heaton, Zomedica's Chief Executive Officer.
Good afternoon, everyone, and welcome. I'm Larry Heaton, the Chief Executive Officer of Zomedica. Thank you for joining us for another Fourth Friday at Four webinar. Whether you're a shareholder, a potential investor, or just someone who loves animals as we do, we appreciate you taking the time to be with us today. Today's session is a little different from many of our previous webinars.
Rather than focusing on a specific product category or market segment, we're going to take a closer look at the framework that guides almost everything we do commercially at Zomedica, what we call our Five Pillars. The Five Pillars represent the lens through which we evaluate opportunities across our business. They influence how we assess new technologies, how we think about acquisitions, how we support veterinary practices, and ultimately how we create long-term value for shareholders.
At Zomedica, we believe success in animal health requires more than simply offering innovative products. Products must solve problems, meaningful problems, for veterinary practices, while also improving patient outcomes and strengthening the relationship between veterinarians and pet parents. Our Five Pillars framework was developed to ensure that every product we bring into our portfolio contributes to these objectives.
This ensures that veterinarians incorporate Zomedica products into their practices, producing inconsistent, ongoing, sustainable, profitable, consumable revenue, providing the foundation for our revenue growth well into the future.
The framework addresses the complete veterinary care journey, from improving the quality of care delivered to the patient, to enhancing the pet parent experience, increasing workflow efficiency, strengthening practice cash flow, and ultimately improving practice profitability. What makes this framework particularly important is that these pillars are interconnected. Better diagnostics can lead to better treatment decisions.
Better treatment decisions, better treatment outcomes can improve client satisfaction and retention. More efficient workflows can increase patient throughput and financial performance. Together, these outcomes create stronger veterinary practices, deeper product adoption, and recurring revenue opportunities that support sustainable growth. Throughout today's webinar, we'll walk through each of the Five Pillars and demonstrate how our product portfolio supports them.
We'll also discuss how this framework helps differentiate Zomedica as we continue building an integrated veterinary health ecosystem designed to support veterinarians, veterinary staff, pet owners, and ultimately our shareholders.
Our goal today is to provide insight into the strategic foundation behind Zomedica's portfolio and to illustrate how clinical value, practice performance, and shareholder value are connected through a single disciplined operating framework. After the prepared remarks are completed, we will, as always, move into a question and answer session with leadership. With that, let's get started.
To understand Zomedica, you need to understand the lens through which we evaluate everything: our products, our partnerships, our investments, and our growth strategy. That lens is the Five Pillars framework. Most animal health companies are built around products. They develop a device. They sell it into clinics and measure success by units shipped. Zomedica was built around a different question. What does a veterinary practice actually need to succeed clinically and financially?
How do we design for that outcome from the start? The answer became our Five Pillars. They represent the full value chain of a veterinary practice, from the examination table to the practice's P&L. The first two pillars address the clinical side of the practice, the quality of care delivered to the pet, and the experience of the pet parent who brings that animal in. These are the outcomes veterinarians entered the profession to achieve.
The next three pillars address the operational and financial side, how efficiently the practice runs, how much revenue it generates per patient, and what margins remain after costs. These are the outcomes that determine whether a practice survives and grows. Together, these five pillars represent what we call Zomedica's dual mandate, serve the pet and serve the practice.
We believe those two goals are not in tension. In fact, products that improve care quality consistently improve practice economics because better diagnostics mean faster decisions, faster treatment, and stronger client relationships. The five pillars are not a positioning statement. They are an operational filter. Before a product enters our portfolio, it must demonstrate a meaningful impact across all five pillars, and after launch, we measure against them. Utilization rates, reorder behavior, clinic retention, all of it maps back to this framework.
This discipline distinguishes Zomedica from companies that assemble product lines through acquisition without a unifying logic. Every product we offer has a defined role in the practice and a measurable contribution to practice performance.
One more thing worth noting for investors, the pillars are interdependent. Improving diagnostic accuracy, pillar one, increases pet parent confidence, pillar two, which drives return visits and compliance, pillars four and five. Improving workflow, pillar three, enables the practice to see more patients in the same hours, which compounds the revenue effect of pillars four and five.
The framework builds on itself. That is by design. With that foundation in place, let's go pillar by pillar, starting with the one that sits at the center of every clinical decision, the quality of care delivered to the pet. The first pillar is the foundation of everything else.
Does the product measurably improve the care that the pet receives? In veterinary medicine, diagnostic accuracy has historically been constrained by access. A general practice veterinarian dealing with suspected hypothyroidism, Cushing's disease, or early cardiac disease has traditionally had two options: send a blood sample to a reference laboratory and wait two to three days for results, or make a clinical judgment without confirmation. Neither option serves the patient or the practice particularly well.
The TRUFORMA platform changes that. Using bulk acoustic wave biosensor technology, it delivers results in 20 minutes or less at reference laboratory accuracy levels. Correlation coefficients across our assay panel range from 0.92 to 0.99 against the predicate gold standard. This is not a screening tool. It is a diagnostic platform that enables confident clinical decisions at the point of care. The clinical implication is meaningful.
Our feline TSH assay is the only assay on the market specifically optimized for cats, capable of detecting the low TSH concentrations that identify 10%-40% of early and mildly hyperthyroid cats whose T4 levels would otherwise appear normal. Our canine ACTH assay is the only in-clinic test that differentiates pituitary-dependent from adrenal-dependent Cushing's disease, allowing the veterinarian to set a treatment course before the client leaves the exam room. These are not marginal improvements. They are diagnostic capabilities that previously did not exist at the point of care.
On the therapeutic side, PulseVet is the gold standard in veterinary shockwave therapy, backed by more than two decades of clinical research across human and animal medicine. The electrohydraulic technology delivers focused, high-energy sound waves to large tissue volumes, stimulating the body's own healing response for musculoskeletal conditions, including osteoarthritis, tendon and ligament injuries, bone fractures, and back pain.
Treatments are completed in under five minutes without sedation, a meaningful clinical and operational advantage. VETGuardian addresses a different but equally important care gap, post-surgical and overnight monitoring. Using patented Doppler radar technology developed at the University of Florida, VETGuardian continuously monitors temperature, pulse, and respiration without any contact with the patient. Customizable alarm thresholds alert staff the moment a vital sign falls outside range. Earlier detection of deterioration means faster intervention and better patient outcomes.
TRUVIEW is the only fully automated digital microscope for veterinary point-of-care cytology. Skin cases, ear cases, fine needle aspirates, results that previously required courier services and reference lab turnaround are now read in-house, same visit. The diagnostic chain stays inside the clinic, and the quality of the answer improves. The automated AI reports for hematology assist the veterinarian identify cellular abnormalities, and a board-certified pathologist is there to provide a consult when needed.
The Assisi LOOP delivers targeted pulsed electromagnetic field therapy, TPEMF, to accelerate the body's natural healing processes. Backed by peer-reviewed research, the Assisi LOOP supports pain management, reduces inflammation, and promotes tissue repair in post-surgical, orthopedic, and wound care patients. It is simple enough for technician administration and compatible with home care protocols, extending quality treatment continuity beyond the clinic visit.
VETIGEL is a plant-derived polymer gel that rapidly controls bleeding in surgical and emergency settings. Applied directly to a wound or surgical site, VETIGEL accelerates clot formation significantly faster than conventional methods, reducing intraoperative blood loss, shortening procedure time, and improving patient safety. In a profession where every minute in the operating room carries cost and risk, that speed matters. Taken together, these products address different moments in the clinical encounter: diagnosis, treatment, monitoring, imaging, and acute surgical care.
They share a common design intent, close the gap between clinical question and clinical answer as quickly and accurately as possible. Better care at the point of care changes what the veterinarian can do. The second pillar addresses what that change means for the person sitting across from them, the pet parent. The second pillar shifts our lens from the exam table to the client relationship, and for investors, this is where clinical value translates into practice economics. The modern pet owner is not the same client veterinary practices were designed for. Today's pet owner expects the same speed, transparency, and communication from their veterinarian that they receive from every other healthcare provider in their life.
Multi-day waits for laboratory results, callbacks with diagnoses delivered by phone, treatment plans discussed without the client present, these experiences erode trust, reduce compliance, and ultimately reduce the lifetime value of that client relationship. In-clinic diagnostics fundamentally change that dynamic. When a veterinarian runs a TRUFORMA panel during the appointment and reviews results with a pet parent in the exam clinic, the conversation shifts. The diagnosis is explained with evidence. The treatment plan is established before the client leaves. Questions are answered in real time. That combination of speed and transparency, same-day immunochemistry results in the exam room rather than a callback two days later, produces a measurably different client experience, one that drives compliance, return visits, and referrals. This matters to investors because client retention is the compounding variable in practice economics.
A practice that retains clients at a higher rate generates more visits per patient per year, more diagnostic events per visit, and more opportunities to utilize the full Zomedica product portfolio. The economics of retention compound over time in a way that new client acquisition simply cannot replicate. PulseVet contributes to pet parent satisfaction in a way that is immediate and tangible. Shockwave therapy typically requires just two treatment visits to complete a full course, compared to 15 or more visits for laser therapy or the open-ended commitment of daily medication protocols. That compression of the treatment timeline directly improves owner compliance because the ask is small and the result is visible. The clinical outcome speaks for itself in the room. A dog that arrived at the clinic limping often walks out noticeably improved after a PulseVet session.
That visible, in-the-moment change is one of the most powerful trust-building events a veterinarian can deliver, and it creates a pet parent who returns, refers, and complies. When a pet is hospitalized, the pet parent goes home without their animal. VETGuardian addresses that moment directly. Because the device monitors continuously temperature, pulse, and respiration around the clock without any staff intervention required, the practice can tell the owner with confidence that their pet is being watched at every moment. That assurance is not a soft benefit. It is a material difference in the client's experience of leaving a vulnerable animal in someone else's care, and it is the kind of communication that builds lasting loyalty to a practice. Pillar two extends beyond the clinic. The Assisi LOOP and Calmer Canine products give pet parents an active role in their animal's recovery.
The Assisi LOOP's TPEMF therapy is designed for home use with simple protocols the owner can follow between clinic visits. For dogs with separation anxiety, Calmer Canine provides a drug-free, targeted treatment the parent administers at home. This matters for two reasons. First, it improves clinical outcomes through consistent treatment continuity. Second, it deepens the emotional engagement of the pet parent with their veterinarian's care plan. A client who is actively participating in their pet's recovery is a more informed, more loyal, and more compliant client. They are also more likely to refer others to the practice that equip them with that capability. Client trust and compliance are outcomes, but they require the right operational conditions to produce them consistently. That brings us to pillar three: veterinarian workflow. The third pillar moves us from the clinical and client relationship into the operational engine of the practice.
Here, the story is straightforward. Veterinary practices are under staffing pressure, capacity pressure, and time pressure simultaneously. Every inefficiency in the clinical workflow has a direct cost in throughput, in revenue, and in staff retention. Zomedica's products are designed to remove friction at the points where it does the most damage. The most significant workflow improvement our diagnostics deliver is the elimination of the reference laboratory send-out cycle. Under a traditional model, a sample is collected, packaged, picked up, processed, and reported, a cycle that takes two to three days, requires a callback to the client, and often results in a second appointment to discuss findings and initiate treatment. Every step in that cycle consumes staff time without generating additional revenue. The TRUFORMA platform eliminates that loop entirely. Results are available in the room in the same appointment. The TRUVIEW digital microscope does the same for cytology.
Slides prepared can be read in-house. No courier, no delay, no rescheduled appointment. TRUVIEW's AI-generated report delivers the interpretation automatically, saving the veterinarian time that would otherwise be spent on manual review. The net effect is not just faster results, it is a meaningfully more efficient use of every appointment on the schedule. PulseVet shockwave therapy sessions can be performed by trained veterinary technicians under DVM guidance. That distinction matters for workflow. While a technician delivers a shockwave session using the PulseVet device, the veterinarian is free to see another patient, conduct a consultation, or complete a procedure that genuinely requires their clinical expertise. The practice gains capacity without adding headcount. The technician gains a high-value clinical role that improves their engagement and utilization. More patients seen per day with the same team. The VETGuardian monitor addresses a different workflow constraint, the overhead of monitoring hospitalized patients.
Manual vital signs checks require staff presence, interrupt other tasks, and create gaps in overnight coverage. VETGuardian's zero-touch platform monitors continuously, alerts on threshold breaches, and generates automatic patient reports. Staff are freed up to focus on active care rather than passive surveillance. The Assisi LOOP and TPEMF therapy protocols are simple enough for non-DVM staff to manage without direct veterinarian oversight, expanding the number of cases a single practice can handle without adding clinical headcount. The cumulative effect of these workflow improvements is measurable. More patients seen per day, more procedures completed per provider, and the same team operating at higher throughput. That is the gateway to adoption. It is why utilization rates remain high and churn rates remain low once our products are embedded in a practice. Efficiency creates capacity. Capacity creates opportunity. Pillar four addresses what that opportunity is worth in direct financial terms.
The fourth pillar addresses one of the most persistent tensions in veterinary practice: the gap between clinical excellence and financial performance. Many veterinarians are outstanding clinicians who are nonetheless operating under significant financial pressure, constrained cash flow, high overhead, and revenue that walks out the door to third-party laboratories and external service providers. Every Zomedica product is designed to address that gap directly by adding a revenue line, retaining revenue that would otherwise leave the practice, or accelerating the payment cycle. TRUFORMA's business model is built on consumable cartridges. Every test is a billable diagnostic event. Every reorder is a recurring revenue transaction. Because TRUFORMA retains that diagnostic revenue inside the clinic rather than routing it through a reference laboratory, the economics are meaningfully different from the traditional send-out model. The practice captures the margin.
The assay menu now spans 18 tests covering thyroid, adrenal, cardiac, gastrointestinal, reproductive, and insulin conditions, all conditions requiring serial monitoring, which drives repeat utilization over months and years. Importantly, there is no upfront capital investment required to begin. The revenue model is consumable first, making adoption accessible regardless of practice size. PulseVet generates high-value therapeutic procedure revenue. Shockwave treatments are billed at premium rates, completed in under five minutes, and require no anesthesia, eliminating the cost and complexity that typically accompany premium procedures. One to three sessions per case, spaced two to three weeks apart, create a predictable near-term revenue stream per patient. The financing model makes the path to positive cash flow clear. With financing, a practice needs to commit only approximately $2,800 in the first 12 months.
At average utilization levels, two to five patients per month, the device generates approximately $36,000 in annual cash flow against a total cost of approximately $34,000, which is set up to be amortized over five years. That means the device pays for itself before it is fully paid off. Every month beyond that is pure margin contribution. This is not a capital burden. It is a cash flow accelerator. TRUVIEW keeps cytology revenue inside the practice. Every case that previously went to an outside laboratory now generates in-house margin. Like TRUFORMA, TRUVIEW requires no upfront capital investment. The barrier to access is designed to be as low as possible, so that revenue capture begins immediately. VETGuardian creates an entirely new revenue line: overnight and post-surgical monitoring billed as a service per hospitalized patient.
The practice charges a monitoring fee for zero-touch postoperative care, a service that previously was absorbed as overhead. Because the monitoring fee recurs with every hospitalized patient, the device generates a new, consistent revenue stream that covers its own cost quickly and then produces ongoing positive cash flow beyond payback. The cash flow compounding effect is worth noting for investors. Faster diagnosis leads to faster treatment initiation, faster treatment completion, and faster billing cycle. Practices that adopt Zomedica diagnostics do not just generate more revenue per visit. They generate it faster, with less administrative friction, and with higher client satisfaction at each step. Revenue is only part of the equation. Pillar five is where cash flow becomes margin and where the compounding financial case for the Zomedica platform becomes clearest. Cash flow is revenue. Profitability is what remains after costs. Both matter, and both are addressed by Zomedica's product ecosystem.
The profitability case begins with margin. In-house diagnostics eliminate third-party laboratory fees on every test run. That margin improvement compounds across every patient, every visit, every month. Practices running high-volume endocrine panels through TRUFORMA are not just generating more revenue, they are retaining more of it per test than they ever could under a send-out model. Workflow efficiency converts directly into labor cost reduction. When VETGuardian handles continuous monitoring, staff hours are reallocated to higher-value tasks. When Assisi LOOP protocols are managed by technicians rather than veterinarians, DVM time is freed for cases that require it. When PulseVet sessions are delivered by a trained tech while the DVM sees another patient, the same hours generate more billable activity. These are not abstract efficiency gains. They reduce overtime, reduce staffing strain, and improve the per-hour economics of every provider in the practice. The most significant profitability impact comes from multi-product adoption.
A practice running TRUFORMA diagnostics, PulseVet shockwave therapy, and VETGuardian monitoring across its patient population is not experiencing three separate revenue streams. It is experiencing a compounding margin improvement. One client relationship supporting multiple high-margin revenue lines with a single sales and support infrastructure serving all of them. For investors, this is the retention story embedded in the profitability pillar. A practice that is measurably more profitable because of Zomedica does not easily switch platforms. The switching cost is not just logistical, it is financial. That stickiness is the foundation of our recurring revenue model. We have walked through each pillar individually. Now let's look at what the framework produces when all Five Pillars are operating together inside a single practice, because this is where the investor thesis becomes most visible. No single product achieves all Five Pillars in isolation. The ecosystem does.
The more completely a clinic integrates the Zomedica portfolio into its daily workflow, the stronger the Five Pillars performance becomes across every dimension. Consider a well-equipped companion animal practice on a typical operating day. In the morning, a dog presenting with suspected Cushing's disease comes in. The veterinarian runs a TRUFORMA Cortisol and eACTH panel. Results are back in under 20 minutes. The diagnosis is confirmed in the room. The treatment plan is established. The pet parent leaves informed and engaged with a follow-up monitoring schedule already on the calendar. That is pillars one, two and four operating simultaneously. Better diagnosis, better client experience, and a billable event completed within the appointment. At midday, a dog with a chronic shoulder injury comes in for a PulseVet shockwave session. The treatment takes less than five minutes, delivered by a trained technician while the DVM continues seeing other patients.
No sedation, no preparation overhead, no recovery time. A premium procedure billed at premium rates, expanding the practice capacity without expanding its headcount. That is pillars three, four and five : workflow efficiency, cash flow, and margin. In surgery, VETIGEL hemostatic gel is applied to control intraoperative bleeding. What previously required prolonged manual pressure or added procedural time is addressed in seconds. The operating room time shortens. The patient's exposure to anesthesia is reduced. The outcome improves. That is pillar one, care quality, operating at one of its most critical moments. Through the afternoon, a postsurgical patient recovering from orthopedic repair is monitored continuously by a VETGuardian monitor. Staff are not standing at the kennel. They are seeing other patients. Alarms are set. The system watches. If anything changes, the team is notified immediately. The pet parent at home has been told their animal is being continuously monitored.
That is pillars one, two, and three: care quality, owner satisfaction, and workflow efficiency running in parallel with no additional labor. Throughout the day, the TRUVIEW microscope is handling cytology on skin and ear cases as they come through. With the slides read in-house, AI reports generated automatically, results communicated in the same appointment. No send-out fees, no delay. Pillars one, three, and four. When patients are discharged, the ecosystem extends beyond the clinic. A postsurgical patient goes home with an Assisi LOOP for continued tPEMF therapy between visits. A dog with anxiety goes home with Calmer Canine, continuing treatment on a schedule the owner manages themselves. The care plan doesn't end at the door, the relationship between the practice and the pet parent deepens with every day of continued treatment at home.
For our commercial team, the multiproduct practice is the primary growth opportunity within the existing installed base. A clinic already using the TRUFORMA platform is a natural candidate for the TRUVIEW microscope and VETGuardian monitor. A clinic using PulseVet shockwave is a natural candidate for Assisi tPEMF therapy as a send-home complement. The framework itself identifies the cross-sell logic because practices that adopt more pillars perform better across all five, they know it. Each product in this picture contributes to multiple pillars simultaneously. Each product reinforces the others, each product deepens the practice's operational and financial dependence on the Zomedica ecosystem, which is exactly the retention dynamic that sustains recurring revenue. A framework is only as effective as the infrastructure that delivers it. Products do not realize their potential through placement alone. They realize it through training, adoption support, and ongoing clinical education.
That infrastructure is built through the partnership between our sales team and our professional services veterinarians. The support model is built around a simple premise. The value of a Zomedica product is not fully captured at the point of sale. It is realized over time through utilization, protocol development, and the gradual integration of that product into a clinic's standard of care. While the sales team helps clinics identify the right solutions for their needs, the professional services veterinarian team helps ensure those solutions deliver meaningful clinical and business outcomes long after the initial purchase. Sales representatives and professional services veterinarians work hand in hand, they serve distinct roles. Sales teams focus on identifying opportunities, understanding clinic needs, and helping practices build the right combination of solutions across the five pillars.
Professional services veterinarians provide the clinical expertise, training, and implementation support that help those solutions become part of everyday practice. Each professional services veterinarian works directly with clinic teams on onboarding, clinical education, protocol implementation, and utilization optimization. They are not order takers. They are veterinarians, educators, and practice advisors who understand how to translate products into clinical workflows. They help uncover unrealized potential within an existing customer base, a practice running the TRUFORMA platform at low volume, a clinic that has a PulseVet device but has not expanded into companion animal indications, or a team that could benefit from incorporating an Assisi LOOP into its treatment protocols. The professional services veterinarian team also provides ongoing customer success support by monitoring utilization trends, troubleshooting adoption barriers, and identifying opportunities to expand clinical applications.
Working alongside sales representatives, they help strengthen customer relationships, increase product utilization, and support growth across multiple product categories. Together, sales representatives and professional services veterinarians transform an installed base into recurring revenue and help clinics evolve from single-product users into multi-pillar partners. The clinical use guide, PulseVet device training resources, and the My Zomedica platform for test result interpretation are all examples of the infrastructure that supports this model. These tools, combined with the expertise of our sales and PSV teams, are designed to deepen utilization, improve customer outcomes, and reduce churn throughout the customer lifecycle. With the full picture in view, the framework, the products, and the delivery model, I'll hand it over to Larry Heaton, our Chief Executive Officer, to close with what this means for investors.
We've covered a lot of ground today. Let me bring it back to the core investment thesis. The Five Pillars are not a marketing tagline. They're an operational framework, a filter that every Zomedica product must pass before it enters the portfolio, and a standard against which we measure performance after launch. That discipline is what keeps the portfolio coherent and what keeps our relationships with veterinary practices durable. Here's what that discipline produces in investor terms. Clinical adoption. Products that measurably improve care quality earn their place in daily clinical workflow. They're not occasional purchases. They're embedded tools that generate recurring utilization because the clinic cannot operate as well without them. Practice loyalty. Practices that are measurably more efficient, generating more revenue and retaining more of it as margin, do not easily walk away from the platform that produced those outcomes.
The switching cost is real, and it compounds with every additional product the practice adopts. Recurring revenue. Consumable pull-through from the TRUFORMA platform, procedure revenue from PulseVet shockwave therapy, monitoring fees from the VETGuardian monitor, product sales from the Assisi LOOP and VETIGEL hemostatic gel. These are not one-time transactions. They're revenue streams that recur at the pace of clinical activity, which in a companion animal practice is measured in visits per week, not projects per year. Scalable growth. The professional services veterinarian's infrastructure that drives adoption in one clinic is the same infrastructure that drives adoption in the next. The framework scales because the logic is consistent. Every practice has the same Five Pillars to address, and Zomedica has the portfolio to address all of them. We believe the Five Pillars represent more than a mission statement. They are the architect of a sustainable, scalable animal health business.
When veterinarians thrive, pets receive better care, pet parents build stronger relationships with their clinics, and Zomedica grows, and the value of your company increases. Let's move on to the Q&A.
We'll now move into the live Q&A section. If you have a question, please drop it into the chat box now. We're here to help. If you have questions later, you can contact us with the contact information shown on your screen.
Okay. Good afternoon. I am a little bit bandwidth-challenged this afternoon, so I won't be on the video, but I'm happy to take each of your questions. Let's jump in here. The first question is basically seeking some additional details regarding our development services segment revenue. Let me see if I can help you with that. We currently are working with three entities. Two of them are in the human space. One is in the animal health space. We, of course, have signed a contract with one of them, ROM Inc. We released that a couple of quarters ago, I think, when we signed it. Of course, any additional contracts that we execute, to the extent that they are material, we'll be issuing an 8-K and most likely a press release as well.
If they're not material, I'll just mention them on this call as we move forward. When we do execute those agreements, I'm happy to give you all the details that our partners are comfortable sharing, and I look forward to doing that as we move forward. Let's see. We have a question, "How is the second quarter looking?" Well, as you know, today, plus two more business days for most of our business and a couple of weekend days for our retail and online business, we're that many days away from the end of the quarter. As you might imagine, we have a really good handle on where we are. Let me just say that we're very much looking forward to releasing earnings on August 5th. We believe that you'll be pleased.
I kind of need to wait until a quarter's over and our auditors have looked at it and so on and so forth to be able to give you additional details. Let's see. There's a question, "What specific steps" Let me see. Where is it? "What specific steps has management taken to reach cash flow breakeven and profitability as soon as possible without dilution? Can you give targets for revenue growth, recurring revenue, cost control, et cetera? How does Zomedica plan to improve shareholder value and market confidence?" First of all, with respect to dilution, of course, dilution would come only if we issued additional shares from raising additional funds. It's obviously a separate issue from cash flow breakeven and profitability. Of course, we have the ability to issue additional shares and sell them into the market because of our charter.
We've had that since the company was incorporated. We believe that we have sufficient capital on board to be able to achieve our objectives of cash flow breakeven and profitability. We would be loath to put additional dilution to our shareholders. We're all shareholders at the company ourselves. Not all of us, but many of us, we understand that. With respect to cash flow breakeven and profitability, increasing revenue at a good clip, producing solid margins. We're producing revenues at good margins, that's going to generate cash, reduce cash burn, and give us a clear pathway to cash flow breakeven. On the other hand, reducing OpEx and limiting CapEx is something that we've been doing quarter-over-quarter and year-over-year for some time now. We expect that to continue.
As we mentioned, we spent time in the earlier years building the infrastructure that we needed, whether it was facilities or manufacturing areas or whether it was just significant investments in R&D to be able to build the products out and get them into the market to assure a good product market fit. As these things have wound down, we've been able to reduce R&D expense. I think you can see that we've right-sized the sales group. We've also right-sized some of the senior management group. As you can tell, there's not as many vice presidents on the website. We will continue to do that. As I've mentioned before, we expect our first quarter of cash flow breakeven to be the end of this year, then of course, for the full year next year.
Targets would be cash flow breakeven and GAAP profitability. Cash flow breakeven for fourth quarter and for the full year next year and GAAP profitability just as soon as we can get it and for 2027. Let's see. "Regarding the CLIP score feature in our ACTH assays, which has been validated by studies like the one from the University of Georgia, how has the feedback been from our partners and veterinarians regarding this feature? Do you believe that providing this additional information was a decisive factor in their positive reception and accelerating their adoption of our product over traditional standards? Building on that, do we have other assays in our portfolio that offer similar technical advantages, meaning they provide data and insights that traditional central labs cannot offer at the point of care?
Is this type of value-added insight your primary focus for strengthening our competitive edge in the market?" Yes, it is one of our focuses. I should say, just to answer the question specifically, right? The CLIP, the additional information provided by providing a CLIP score in addition to a total ACTH score, has been received very well by equine academic veterinarians, researchers, and those types of internal medicine veterinary equine vets who are focused on this disease condition. They were very excited about it. Mainstream equine vets, I think they find it of interest, but really what they're looking for is a composite score that's going to match up with the reference ranges that were established over the years by Cornell's test. Up until recently, that's the only place you could get it. The reference ranges were established with those scores, which included both ACTH and CLIP.
What mainstream vets want to know is the score I'm getting from your TRUFORMA device, does it use the same reference range? Does it match up with Cornell? The University of Georgia, by validating that that composite score was right on with Cornell, that delighted, I think, mainstream vets whose primary sort of attraction to the product is that they can do it at the point of care. They don't have to take the blood, keep it cold, get it back to the clinic, send it frozen or cold to New York, and then wait days or longer to get a score back. What the validation did is it gave them confidence that, "Yeah, this is something I can substitute." That, I believe, is why we're seeing really high levels of adoption in the equine community with this product. Couple of reasons.
One, some because of the CLIP score, some because it's validated by the UGA, most because it's available at the point of care. Many of those, it was the expansion of our assay line. If you recall, we launched ACTH for horses first, and it had pretty good reception. It wasn't yet validated by the UGA on this and that, but it's used in conjunction with insulin. Most vets, if they're going to do a new horse and test them, they're going to look at both eACTH and insulin at the same time before they make a final treatment decision. At first, we didn't have insulin at the point of care, so they were going to have to get that somewhere else. Now we do have insulin at the point of care.
Soon we'll have both insulin and ACTH on the same cartridge. I think addition of insulin, well, I know it did. It also boosted sales. Then not to leave out Boehringer Ingelheim's program, that also allowed us to have our message heard, not only by our own salespeople and our own marketing activities, but also by BI. All those things together. Now, other assays. It underlines a couple things. One, we should continue to have our assays validated by universities, sponsoring clinical research to have them be able to publish to their peers that the product is spot on is worth doing. It's worth the investment. Second, additional assays that complement our existing assays so that they can get more of their tests done by one piece of equipment is also smart.
To that end, we do have a couple more, actually three more equine assays that we're planning on launching this year. We're going to continue that. Other than equine, if you look over, I think just from this presentation today, you heard that TSH assay is the only feline-optimized assay. You might recall that there was a publication done out of New York that indicated that if you would use the reference lab, forget point of care, if you'd use the reference lab test, you would have misdiagnosed 25% of the patients of the cats, because you weren't using our TSH, you were using a canine assay. We have very high penetration in the feline market as well. As you can imagine, we continue to look for assays that are both unique and also very important to veterinarians.
Here's a question referencing a fire that occurred at a medical distributor out in Tracy, California. Not far from where my family and I used to live, by the way, R. Wilson. They were encouraging us to be super careful, make sure that we have safety first in mind and so on and so forth. I'll just assure you that is the case. Our team is on top of these kinds of things. In fact, about a year ago or so, I think we switched insurance providers and went through a complete audit with the insurance people of both of our main facilities. If they had felt like there was something out of whack, they certainly would've told us.
I meet weekly, actually, directly with the head of operations. He keeps me very well informed about any issues that have to do with the health or safety of our staff. Let's see. What are you most proud of from Q2, and what are you most excited about for Q3? I'm excited that in Q3, on August 5th, I can tell you about what we're super proud of from Q2. Realistically, you need to wait a little bit. August 5th, we'll let you know. We believe it's good news that you'll very much appreciate. In Q3, we have a couple of product launches that we are going to be executing. We have some really exciting things that we're doing at the GPO level in the veterinary community. Of course, we're always working on our development services projects.
We'll fill you in on those coming up. Which international area or country do you expect the most growth for the rest of 2026? That's a good question. It really depends on the rate of it's a question about growth as opposed to total volume. Our international sales are up significantly. I'm really looking forward to giving you those metrics in early August. Up significantly. We're seeing really good uptake from our U.K. distributor. Our EU master distributor for equine continues to do very well. We have introduced some products into several new countries, and in fact, in a couple of instances, they're doing some evaluations that could be very significant for us. I will say that international growth is very strong. In terms of where we expect the most growth, I think the U.K. is one that's really been taking off.
They do trade shows over in the U.K. The nice thing here is that the distributors are responsible for the expense of those trade shows. Our VP of international, who you've seen before on some of these videos, Paul Tai, attends those. He's been very positive about the impact of those. I think the biggest growth will come out of distributors that we start up, because it'll go from nothing to whatever it is in that particular environment. Where do you see share prices moving forward? I think that's a wonderful question. If we knew that answer specifically, then we'd be better off than the whole rest of the world. We're going to continue to build the fundamental value of the company.
We're going to continue to increase revenue, maintain high margins, continue to drive OpEx down, limit CapEx, get to cash flow breakeven, and get to profitability, announce new product launches, talk to you about the kinds of things that we have today, which we believe lay the foundation for strong consumable growth as we move forward. As long as that consumable growth continues to grow and grow, if those are things that are going to move the share price, then we expect those share price to move. Can we speak on the partnership with Boehringer is going? It's actually going very nicely. Their program is generally for a set period of time, and we did very well working with them. I should say it's two set periods of time, one in the spring and one in the fall.
The spring program officially ended, the BI folks asked us if they could continue to offer our TRUFORMA, and of course, we said, "Sure. Be happy to have you do that." Also, we're going to be involved in supporting some additional training of their sales team. They've expressed that they'd like to know even more about how the TRUFORMA works as opposed to just say, "Hey, it works, and it's validated." They're going to also do the same program in the fall. It just has to do with when you can test for these conditions. I could bring a vet on to answer why that exactly is. I'm not sure I really know. I just know it's spring and fall. Now, in Canada, they only do one program a year, and that's for the fall.
In Canada, the fall begins in August, and Canada's asked us to do a similar program in Canada as we did in the U.S. We've got Paul checking with the BI subsidiaries outside the U.S. We think it's a good program, and we expect to continue for many times, many years, quarters, years ahead. Let's see. "The investment thesis is clear. Clinical adoption, recurring revenue, increased loyalty, scalable growth through the sales and professional services vet model." Yes. "From a shareholder perspective, can management quantify the actual scale and results behind this model, including current installed base and so on and so forth?" I'll just repeat what we've said before. I understand that you'd like to have it. We don't provide that level of detail on the product segments.
In the future, perhaps we will, we see this as both a competitive intelligence issue as well as one that just doesn't lend itself to month-by-month updates and so on and so forth. We encourage you to review our earnings on August 5th when we release them next. We'll continue to provide detail at the segment level. Beyond that, we're going to keep that to ourselves. I think the best example of that is there's a competitor that was able to add one of our assays onto their machines and then tell the people that were using their machines that they should use their assay. We're going to keep close to the vest things that we think would somehow inhibit our ability to continue to build a market in the way that we want to.
We actually have a little surprise for that particular company because we have something doing with that assay that will, I think, bring those customers that did go back to that, I think we'll bring them back our way. Let's see, what else? "What key KPIs should shareholders track?" For us, I think our answer would be revenue margins, cash flow, or cash burn. Right? Our OpEx levels, CapEx levels. These are the ones that I think are most important and the ones that we're primarily focused on. "Any coming catalysts that could push the share price significantly higher?" I think that's really in the eyes of the beholder. I certainly think we got lots of catalysts that should push it higher.
I know it'll push it higher for me individually, but for shareholders, it's been tough to see the connection between our performance and the performance of the share price, I think, as you all know. We'll leave that to the market. "Thoughts on expanding the human health industry?" We are sort of doing that, but through partners in our development services segment. It's a different paradigm to get into the human health business from a regulatory standpoint and from an investment in the kinds of clinical research you need to do, as well as the commercialization effort. The last thing I think our shareholders would want is for us to go out and raise additional capital to be able to invest in the human side, at least at this point. Once we get beyond the cash flow breakeven and profitability, who knows in the future.
But for now, we're choosing to do that through human health partners. "What is the customer growth for adoption of the product line in the U.S. versus international? Is one driving it faster than the other?" The volume of growth, the growth in absolute terms in terms of units and actual customers is, well, I should say, is higher in the United States. It's a much bigger market and so on and so forth. The percentage growth is higher international. Actually, I think we'll compare those rates when we issue earnings. They're similar, and they have been similar in that international has maintained a fairly steady pace in terms of percentage of our total revenue. International is off a smaller base, so percentage growth's a little higher, or can be a little higher from the same number of units increase.
But in the U.S., we're very pleased with the growth rate that we're seeing. "Can you please speak to the growth opportunities with practice outside the U.S., Canada, Europe, and so on?" I let my earlier comment speak for itself. Canada is interesting. We've always handled Canada directly, and what we found is that once we got beyond PulseVet, which is a capital sale that you sell it once and then you're sending up about four times a year additional trodes, three or four times a year. That's been okay. What we found with our additional products, though, the Canadian distributor was the right choice for us, and the Canadian sales are up significantly, not only in the new products, but also in the PulseVet, which we had been handled directly. That's a nice area for growth for us, and we'll continue to expand on that.
Europe, as I mentioned, we have a master distributor for Equine, PulseVet, All Around, and TRUFORMA all across the EU. We're adding distribution for small animal products. Our first one there really was Pioneer in the U.K. Let's see. There's questions about which of these catalysts we think are going to be the most meaningful. I think that really plays out over time. Each of these, we put our full effort behind each of them, and as they materialize, as we execute, materialize, then we see which of them are most impactful. In any event, we do believe that we will. The question finishes by saying whether they're enough to support their Q4 cash flow breakeven goal. We believe that's the case.
How is the ROM business doing?" I think it's doing pretty well, at least evidenced by the number of units that we've been asked to manufacture for them. We're not involved in the day-to-day of that business. Let's see. Tony's not with us. The fellow who's closest to that business doesn't happen to be on the call today. Maybe we can address him next time around, but we think it's going well. That's just for the prison, what do they call it? Cell-Guardian, like a prison cell, Cell-Guardian business. Then I think they're getting ready to get started with their Silver-Guardian, which is for elderly folks. As they launch that'll be new opportunities for us. Then I think they're also working on one for little tiny folks, infants. I'm mentioning that because they've been public.
They've spoken publicly about that, and in the social media. I'm not saying something that they are keeping quiet. "It seems you're doing the right things for fundamental development and growth. Patience is a virtue. That is what we want. No financial engineering." Thank you very much. "Since management does not want to disclose product-level KPIs, what public milestones should shareholders watch between the earnings and the year-end to confirm the cash flow breakeven is still on track? Revenue growth?" Yes. "Gross margin?" Yes. "Cash burn?" Yes. "OpEx, CapEx reduction?" Yes. "Product launches?" Yes. "GPO activity?" Yes. "International growth?" I'm sorry, I didn't see there was going to or at the end of it.
I think those are all things that are important to see, and at the end of the day, if we're looking for cash flow breakeven, I think obviously the most important one of those would be cash. "Update on PIMS integration?" I think that'll be the last. It's the last question I have as of now, and it'll be the last one that we address because we're right at five o'clock. PIMS integration is going very nicely. Our plan is, or the way we're doing it is we're connecting everything that we want to integrate with the PIMS to our My Zomedica portal, and cloud, and then My Zomedica in turn, we're connecting to PIMS. We actually are live now in several accounts testing or piloting PIMS integration between My Zomedica and one of the most, I should say, the largest market share PIMS provider in animal health.
I think there's another one that they're going to test as well. That actually is occurring now. Our target was to have it done by June, and it's toward the end of June, but June it is. Once that proves out, it's just an iterative where we connect more of our equipment to My Zomedica, and then we connect to more of the PIMS things. We're right on track to have all that completed in the September timeframe. All the products that we want to connect, connected to all of the PIMS providers that make sense to provide. I'm sure there's some out there that have just a handful of accounts and might not be done with all of them, but the major small animal and equine providers will be connected by, we believe, September.
With that, I will thank you again for attending our Fourth Friday at Four webinar and for your continued support of Zomedica. I appreciate your interest in our company, and I'm happy to answer questions. You can reach out. I think you had the information on the screen, but I think you know how to get ahold of us. As I mentioned, we look forward to talking to you at the end of August and issuing our release very early August for the second quarter of 2026. Thank you very much, and I hope you have a great July 4th holiday coming up. Thank you.